Amcham Chile

Isidora Errazuriz
Project Coordinator 
Lorena Palomo
COO 

Business France

Alex Blanchot

Business Sweden

Business developer and investment advisor within healthcare & life science and bioeconomy. Working with U.S. investors and companies and the Swedish industry.

Co-host together with DNB Healthcare Banking and NASDAQ of the Nordic-American Life Science Conference in New York on November 14, 2017. www.nalsconference.com

Mats Shore
Project Manager 
Bio

Working with U.S. healthcare & life sciences investors and companies and the Swedish industry.

Manager of the Nordic-American Life Science Conference on November 14 in New York. www.nalsconference.com

Massachusetts Life Sciences Center.

Ben Bradford
Director for Business Development 

Massachusetts Medical Device Development Center (M2D2)

Stephen McCarthy
Founder & Co-Director 
Mary Ann Picard
Associate Director 

National Institute of Health (NIH)

Daniel Gossett
Program Director, National Institute of Diabetes and Digestive and Kidney Diseases 
Stephanie Fertig
Program Director, NINDS Small Business Programs, NINDS 
Bio

Stephanie J. Fertig joined the National Institute of Neurological Disorders and Stroke (NINDS) in 2004 and currently serves as the Director for the NINDS Small Business Programs, which includes both small business innovative research (SBIR) and small business technology transfer (STTR) projects. Prior to this role, Ms. Fertig was part of the Repair and Plasticity cluster at NINDS, where her primary scientific interests included neural engineering and neuroprosthesis, as well as traumatic brain injury. Before coming to NINDS, Ms. Fertig earned a B.S. degree in Chemistry with a major in Physics from the University of Virginia, Charlottesville. After completing her degree, she joined Nova Research, Inc. and worked as a researcher in the Center for Bio/Molecular Science and Engineering at the Naval Research Laboratory (NRL) in Washington D.C. At NRL she contributed to multiple bioengineering projects, including the development of molecular switches, microbial fuel cells, microfluidics for use in biosensor applications, and a wide variety of biosensor systems. Ms. Fertig also received a M.B.A. from the University of Maryland's Robert H. Smith School of Business in 2007.

Todd Haim
Program Director 

Parkinson's UK United Kingdom

Parkinson's UK supports projects that aim to bring new treatments or a cure to Parkinson's, at the drug discovery and early clinical develoment stages.  Typically support is at the level of $0.5M - $2M per year.  We prefer to invest in projects in a virtual company model but may also invest at the pre-company stage or in projects in existing larger companies.  Treatments directed at broadly applicable neurodegeneration mechanisms such as neuroinflammation and oxidative damage are within our scope, as are symtomatic treatments.  Funding recipients may be located in the UK, Europe or overseas.

Arthur Roach
Director of Research 
Bio

Arthur Roach is representing both Parkinson's UK and Chord Therapeutics at this meeting.

Arthur Roach is Director of Research at Parkinson’s UK, where he is responsible for the strategy to convert the demands and priorities of people living with Parkinson’s into better treatments and a deeper understanding of the condition.  In the current five-year strategic period Parkinson’s UK is investing £40 million in university research grants, international collaborations and data sharing, drug discovery and early clinical development of new treatments, and promoting the greater involvement and participation of people with Parkinson’s in research.  He brings to this role over 25 years of experience of research into Parkinson’s, Alzheimer’s, multiple sclerosis and other neurodegenerative diseases and the discovery and development of new treatments (DuPont, Bristol-Myers Squibb, Merck Serono).

Arthur is also the founder of Chord Therapeutics, a single-asset virtual biotech dedicted to clinical development of CRD1 as a new treatment for neuromyelitis optica and other rare autoimmune neurological conditions.  Chord  is seeking financing for a three-year programme to establish clinical proof of concept in two indications.

UCSF Entrepreneurship Center

Stephanie Marrus
Director 

UNC KickStart Venture Services United States

KickStart Venture Services, part of the UNC-Chapel Hill Office of Commercialization and Economic Development (OCED), supports faculty startup formation, business development and growth by providing coaching and mentoring, early-stage funding, connection with key service providers, management, investors and space.

 

We will be at the meeting representing a number of early-stage life science investment opportunities. A preview of opportunities can be found here: https://goo.gl/jn2gge

Don Rose
Don Rose
Director, KickStart Venture Services 

US China Innovation Alliance

US-China Innovation Alliance (UCIA) helps healthcare companies connect to Chinese capital and partners. Through online and offline platforms, we can help healthcare companies worldwide get access to investors, manufacturers, clinical and research partners and important industrial players.


BiotoChina online pitch (www.biotochina.com): present to Chinese investors from your own computer (Selection required, free to attend)


InnoSTARS competition (http://www.uschinainnovation.org/innostars/): Semi-finalists can go to China for an all-expenses-paid 7-day business trip with arranged meetings. Finalists can get cash prize up to $60,000 and more in investment, great promotion opportunity and be introduced to targeted investors. (Free to apply, InnoSTARS 2018 opens in Jan, 2018)


US China Innovation and Investment Summit (UCIS) (http://uschinainnovation.org/ucis/): Learn about trend of China oversea investment and meet Chinese investors in Houston. Pre-arrange meetings through matchmaking systems. (UCIS 2018 will be held in May, 2018)


The US-China Innovation Alliance (UCIA) is a non-profit 501(c)(3) tax-exempt organization that promotes innovation through the exchange of ideas and collaboration between China and the US. We organize the annual US-China Innovation and Investment Summit (UCIS) in Houston, which provides a unique opportunity for innovative technology startups to connect with investors, strategic partners, leading incubators/accelerators, and professional services firms from China. It is an excellent platform for technology companies to leverage significant resources from China to accelerate their growth and to expand their market potential. In 2017, we launched the InnoSTARS Competition, which allows growth-stage technology companies in five core industry areas to compete for the chance to win attendance to UCIS as well as an all-expenses-paid roadshow to China, where they will have an opportunity to showcase their business and products to a wide audience of qualified potential investors and relevant partners. The UCIA also organizes roadshows to bring innovative US technology companies to China for B2B matchmaking and provides other services to help US-based companies connect with complimentary Chinese resources.

XinXin Li
XinXin Li
Director 
Bio

 Xinxin is founding director of US China Innovation Alliance (UCIA) and currently serves as Director of Development. She is responsible for outreach and partnership of UCIA and oversees various programs including InnoSTARS Competition and BiotoChina online pitch, focusing specifically in healthcare and biotechnology. Xinxin earned a B.S. in Chemistry from Peking University from China and an M.S.P.H in Environmental Health from University of North Carolina at Chapel Hill.